#Vienna #Austria #Longevous Beamtech #LB-30 #radionuclide production

Longevous Beamtech Unveils LB-30 Series Cyclotron

At the recent 39th Annual Congress of the European Association of Nuclear Medicine (EANM 2026) held at the Austria Center in Vienna, Longevous Beamtech (LBT) introduced its state-of-the-art LB-30 series—a 30 MeV medical cyclotron platform. This groundbreaking launch adds a significant new dimension to LBT’s existing range of medical cyclotrons, designed to cater to the evolving demands of radionuclide production and radiopharmaceutical research. The LB-30 series was showcased during a dedicated launch event at the congress, which took place from October 17 to 21, 2026.

Expanding Capabilities

The LB-30 has been engineered to address the increasingly diverse requirements for radionuclide production as the field of radiopharmaceutical development progresses. Various research institutions and pharmaceutical companies are investigating a wider array of radionuclides beyond the traditional PET isotopes used in routine clinical applications. The LB-30 series features cutting-edge technology, including:

• - Multi-Particle Compatibility: Capable of managing various particle types for targeted applications.
• - Continuously Variable-Energy Beam Extraction: Provides adaptability in beam energy output.
• - High-Efficiency Beam Transport: Ensures effective energy transfer throughout the system.
• - Clean Vacuum Technology: Enhances operational efficiency and reliability.
• - Flexible Target Station Solutions: Supports myriad target configurations tailored for diverse irradiation needs.

These features empower researchers and producers with the versatility needed to support a broader spectrum of radionuclide production pathways and applications, thereby enhancing both diagnostic and therapeutic radiopharmaceutical research.

Integrated Production Solutions

In addition to the LB-30 cyclotron, Longevous Beamtech emphasizes an integrated approach to the production workflow of radionuclides and radiopharmaceuticals. LBT's offerings expand beyond cyclotron technology to include:

• - Target Systems: Specialized tools designed to maximize radionuclide yield.
• - Radiopharmaceutical Synthesis and Dispensing Solutions: Streamlining the transition from production to clinical application.
• - Hot Cells and Quality Control Solutions: Providing the necessary safety and compliance checks integrated within production facilities.
• - Engineering, Installation, and Training Services: Ensuring that facilities are set up accurately and operated safely.

By offering such a comprehensive suite of technologies and services, LBT supports a range of production requirements tailored to specific isotopes, volumes, and research objectives, making it a reliable partner for hospitals, radiopharmaceutical developers, and academic institutions.

Engaging with the Community

The LB-30 was warmly received at EANM 2026, where LBT engaged with a diverse audience of nuclear medicine professionals, researchers, and industry partners. The congress provided a platform for fruitful discussions about the future of radionuclide production, highlighting the evolving technical requirements for modern production facilities.

With the introduction of the LB-30, Longevous Beamtech continues to position itself as a leader in the medical cyclotron market. This innovative platform not only enhances the company's existing portfolio but also represents a significant step forward in the capacity for higher-energy, multi-purpose radionuclide production, fostering advancements in the field of radiopharmaceutical research.